Candel Therapeutics (CADL) Corporate presentation summary

Pipeline overview and clinical programs

• Aglatimagene besadenovec (CAN-2409) is an off-the-shelf, pan-solid tumor therapy with positive phase 3 results in prostate cancer and phase 2a results in pancreatic and NSCLC, receiving multiple FDA designations.

• Linoserpaturev (CAN-3110) is an oncolytic HSV-1 virus with proof of concept in recurrent high-grade glioma, published in top journals, and holds Fast Track and Orphan Drug Designations.

• Both products follow a "pipeline in a product" strategy, targeting multiple large indications and supported by a strong executive and advisory team.

• Financial runway is secured into Q1 2028, with recent funding agreements and robust IP protection for both lead assets.

• Precommercialization activities for aglatimagene are underway, including market access and stakeholder engagement.

Prostate cancer: phase 3 clinical trial results

• Statistically significant improvement in disease-free survival (DFS) with aglatimagene plus radiotherapy vs. radiotherapy alone (HR 0.70, P=0.0155).

• 38% reduction in risk for prostate cancer-specific recurrence (HR 0.62, P=0.0046).

• Higher pathological complete response at 2 years (80.4% vs 63.6%, P=0.0015) and more patients achieving PSA nadir <0.2 ng/mL.

• Lower incidence of serious adverse events and treatment discontinuation in the aglatimagene arm.

• Large addressable market ($10–16bn) with clear unmet need and strong payor support for reimbursement.

NSCLC: phase 2a clinical trial results

• Median overall survival (mOS) of 25.4 months in patients with inadequate response to immune checkpoint inhibitors, exceeding historical controls.

• mOS of 21.5 months in patients with progressive disease at baseline, with 50% alive >2 years post-treatment.

• Pronounced benefit in non-squamous NSCLC (mOS 25.4 months per protocol; 16.7 months ITT), compared to 9.9–12.3 months with standard chemotherapy.

• Systemic abscopal effect observed in two-thirds of patients with multiple lesions.

• Favorable safety profile with mostly mild to moderate adverse events.